Eradication of chronic myeloid leukemia stem cells: A novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib

PLoS Computational Biology

Volumn 5, Issue 9, 2009, Pages

  Foo, Jasmine ^a   Drummond, Mark W ^b   Clarkson, Bayard ^a   Holyoake, Tessa ^b   Michor, Franziska ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOLOGY; DISEASES; PATIENT TREATMENT;

BONE MARROW; CHRONIC MYELOID LEUKEMIAS; GRANULOCYTE-COLONY STIMULATING FACTOR; IMATINIB; IMATINIB MESYLATE; LEUKEMIA STEM CELLS; PERIPHERAL BLOOD; PILOT STUDIES; STEM-CELL; THERAPEUTIC BENEFITS;

STEM CELLS;

BCR ABL PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; DRUG MECHANISM; DRUG PULSE THERAPY; HUMAN; LEUKEMIA CELL; LONG TERM CARE; MATHEMATICAL MODEL; MINIMAL RESIDUAL DISEASE; PREDICTION; RISK FACTOR; SENSITIVITY ANALYSIS; STEM CELL MOBILIZATION; TREATMENT RESPONSE; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG POTENTIATION; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIFFERENTIATION; COMPUTER SIMULATION; DRUG SYNERGISM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; PIPERAZINES; PYRIMIDINES;

EID: 70349673335     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1000503     Document Type: Article

References (51)

1. Bruce WR, Van Der Gaag H (1963) A Quantitative Assay for the Number of Murine Lymphoma Cells Capable of Proliferation in Vivo. Nature 199: 79-80.
2. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648. (Pubitemid 24067706)
3. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, Flores T, Garcia-Sanz R, et al. (2000) A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia. Blood 95: 1007-1013. (Pubitemid 30062725)
4. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
5. Hope KJ, Jin L, Dick JE (2004) Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 5: 738-743. (Pubitemid 39023306)
6. Wang JC, Dick JE (2005) Cancer stem cells: lessons from leukemia. Trends Cell Biol 15: 494-501. (Pubitemid 41253469)
7. Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340: 1330-1340.
8. Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293.
9. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037. (Pubitemid 32267972)
10. Holtz M, Forman SJ, Bhatia R (2007) Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res 67: 1113-1120. (Pubitemid 46270768)
11. Cortes J, O'Brien S, Kantarjian H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104: 2204-2205. (Pubitemid 39297882)
12. Ghanima W, Kahrs J, Dahl TG 3rd, Tjonnfjord GE (2004) Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. Eur J Haematol 72: 441-443.
13. Higashi T, Tsukada J, Kato C, Iwashige A, Mizobe T, et al. (2004) Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. Am J Hematol 76: 275-278. (Pubitemid 38828850)
14. Mauro MJ, Druker BJ, Maziarz RT (2004) Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 28 Suppl 1: S71-73.
15. Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, et al. (2005) Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90: 979-981. (Pubitemid 41020302)
16. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, et al. (2005) Dynamics of chronic myeloid leukaemia. Nature 435: 1267-1270.
17. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, et al. (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109: 58-60. (Pubitemid 46053043)
18. Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8: 1018-1029. (Pubitemid 47629897)
19. Ponchio L, Conneally E, Eaves C (1995) Quantitation of the quiescent fraction of long-term culture-initiating cells in normal human blood and marrow and the kinetics of their growth factor-stimulated entry into S-phase in vitro. Blood 86: 3314-3321.
20. Bradford GB, Williams B, Rossi R, Bertoncello I (1997) Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. Exp Hematol 25: 445-453. (Pubitemid 27226863)
21. Arai F, Suda T (2007) Maintenance of quiescent hematopoietic stem cells in the osteoblastic niche. Ann N Y Acad Sci 1106: 41-53. (Pubitemid 47443041)
22. Orford KW, Scadden DT (2008) Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet 9: 115-128.
23. Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, et al. (2008) Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 135: 1118-1129.
24. Foudi A, Hochedlinger K, Van Buren D, Schindler JW, Jaenisch R, et al. (2009) Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells. Nat Biotechnol 27: 84-90.
25. Gothot A, Pyatt R, McMahel J, Rice S, Srour EF (1997) Functional heterogeneity of human CD34(+) cells isolated in subcompartments of the G0/G1 phase of the cell cycle. Blood 90: 4384-4393.
26. Uchida N, He D, Friera AM, ReitsmaM, Sasaki D, et al. (1997) The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. Blood 89: 465-472. (Pubitemid 27051681)
27. Glimm H, Oh IH, Eaves CJ (2000) Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0). Blood 96: 4185-4193.
28. Cashman J, Dykstra B, Clark-Lewis I, Eaves A, Eaves C (2002) Changes in the proliferative activity of human hematopoietic stem cells in NOD/SCID mice and enhancement of their transplantability after in vivo treatment with cell cycle inhibitors. J Exp Med 196: 1141-1149. (Pubitemid 35304181)
29. Passegue E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL (2005) Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med 202: 1599-1611. (Pubitemid 41746605)
30. Holyoake T, Jiang X, Eaves C, Eaves A (1999) Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94: 2056-2064. (Pubitemid 29430422)
31. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, et al. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99: 319-325.
32. Drummond MW, Heaney N, Kaeda J, Nicolini FE, Clark RE, et al. (2009) A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia.
33. Komarova NL, Wodarz D (2005) Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A 102: 9714-9719. (Pubitemid 40981746)
34. Dingli D, Michor F (2006) Successful therapy must eradicate cancer stem cells. Stem Cells 24: 2603-2610. (Pubitemid 46052998)
35. Michor F, Iwasa Y, Nowak MA (2006) The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proc Natl Acad Sci U S A 103: 14931-14934. (Pubitemid 44527831)
36. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, et al. (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 12: 1181-1184. (Pubitemid 44527354)
37. Komarova NL, Wodarz D (2007) Effect of cellular quiescence on the success of targeted CML therapy. PLoS ONE 2: e990.
38. Michor F (2007) CML blast arises from progenitors. Stem Cells 25: 1114-1118.
39. Kim PS, Lee PP, Levy D (2008) Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput Biol 4: e1000095.
40. Strife A, Clarkson B (1988) Biology of chronic myelogenous leukemia: is discordant maturation the primary defect? Semin Hematol 25: 1-19.
41. Holyoake TL, Jiang X, Drummond MW, Eaves AC, Eaves CJ (2002) Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia 16: 549-558. (Pubitemid 34449732)
42. Jorgensen HG, Copland M, Allan EK, Jiang X, Eaves A, et al. (2006) Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 12: 626-633. (Pubitemid 43166158)
43. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880. (Pubitemid 32743979)
44. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, et al. (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99: 3472-3475. (Pubitemid 34525335)
45. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, et al. (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102: 276-283. (Pubitemid 36759665)
46. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125. (Pubitemid 41039112)
47. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, et al. (2002) Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100: 1014-1018. (Pubitemid 34832631)
48. Oller AR, Rastogi P, Morgenthaler S, Thilly WG (1989) A statistical model to estimate variance in long term-low dose mutation assays: testing of the model in a human lymphoblastoid mutation assay. Mutat Res 216: 149-161. (Pubitemid 19155294)
49. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, et al. (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blastcrisis CML. N Engl J Med 351: 657-667. (Pubitemid 39063268)
50. Wang Y, Cai D, Brendel C, Barett C, Erben P, et al. (2007) Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 109: 2147-2155. (Pubitemid 46348217)
51. Hamilton AHG, Allan E, Alcorn M, Nicolini F, Blair A, Schemionek M, Koschmieder S, Brunton V, Holyoake T (2008) Growth Factor Deprivation Combined with Prolonged Inhibition of BCR-ABL Does Not Eradicate Functional CML Stem Cells. Blood (ASH Annual Meeting Abstracts) 112.